Otsuka Pharmaceutical
-
FDA Approves First Drug for Treating Agitation in Alzheimer’s Patients
Rexulti, a drug for schizophrenia and depression, now has an additional approval for treating agitation in Alzheimer’s disease patients. The FDA decision makes the Otsuka Pharmaceutical and Lundbeck product the first drug approved for this indication.
-
Claiming Akebia agreement breach, Otsuka seeks to end anemia drug pact
Otsuka Pharmaceutical is ending its alliance with Akebia Therapeutics, a move that comes less than two months after the FDA rejected their partnered anemia drug, vadadustat, and asked for another clinical trial. Otsuka alleges unspecified breaches of the agreement by Akebia, and ending the alliance early could spare it from spending hundreds of millions of dollars more on the drug.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Merck partners with Taiho, Otsuka in $2.5B bet on KRAS-targeting cancer drugs
The companies said Monday that they would partner to develop small-molecule oncology drugs against several targets, including KRAS mutations, long thought “undruggable.” Amgen and Mirati have already presented clinical data from their KRAS programs.
-
Has the FDA been approving some drugs without proper evidence?
Several FDA approvals – including ones going against AdCom votes – have attracted controversy and a perception of lowered standards at the agency. However, some see a long-standing institutional tension between patient protection and speedy approval, with the latter having a net positive effect.
-
MIT researcher alleged to have copied antibody research Otsuka later acquired evaluating potential legal action
In an article published in the journal mAbs Monday, executives from Adimab alleged that MIT’s Ram Sasisekharan copied prior monoclonal antibody research. Visterra, a company Sasisekharan founded that had been developing one of the antibodies, was acquired by Otsuka for $430M last year.
-
Can ‘new science’ cure biopharma’s ‘compressive disruption’ problem?
A new report by Accenture suggests that over the next three years, 54 percent of biopharma industry revenues could come from new advancements in medical science and technology – and combinations of the two.
-
FDA gives greenlight to first digital ingestion tracking system
Abilify MyCite, developed in collaboration between Proteus Digital Health and Otsuka Pharmaceutical, has an ingestible sensor embedded in the pill which records that the medication was taken. It reflects a trend by companies to use sensors to quantify the effectiveness of medications.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.